Same prompt, very different results.

Discover how Chris uses Replit Agent 3, an advanced AI coding assistant, to build a functional invoicing app for contractors ...

Shares of Replimune Group, Inc. (REPL) have gained 0.7% over the past four weeks to close the last trading session at $7.76, but there could still be a solid upside left in the stock if short-term ...

Replimune Group beat estimated earnings by 7.000000000000001%, reporting an EPS of $-0.77 versus an estimate of $-0.83. Revenue was down $0 from the same period last year. The company missed on EPS by ...

A critical vulnerability in the popular expr-eval JavaScript library, with over 800,000 weekly downloads on NPM, can be exploited to execute code remotely through maliciously crafted input. The ...

The biotech received the good news it was hoping for from a top national regulator. This concerned RP1, its advanced melanoma drug. Well before market open, Replimune announced that the U.S. Food and ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

The last time I spoke about Replimune (REPL) it was with respect to a Seeking Alpha article entitled "Replimune: Scope Goes Beyond That of RP1 Oncolytic Targeting For Melanoma." With respect to this ...

It was the subject of a recommendation downgrade from an analyst. Another pundit reiterated his neutral stance on the company. Rama based much of his new take on the company on the latest developments ...